Abstract: Disclosed are methods for diagnosing CAT1-related diseases, wherein the methods include detecting CAT1 in a cell by a BLV.RBD ligand, or a variant or a fragment thereof. Also disclosed is a BLV.RBD ligand, or a variant or a fragment thereof for use in the treatment of CAT1-related diseases and/or BLV infections.
Type:
Grant
Filed:
November 18, 2016
Date of Patent:
February 7, 2023
Assignees:
METAFORA BIOSYSTEMS, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, UNIVERSITÉ DE MONTPELLIER, UNIVERSITÉ PARIS CITÉ
Inventors:
Svilena Ivanova, Donatella Giovannini, Julien Bellis, Jawida Lezaar, Vincent Petit, Jean-Luc Battini, Marc Sitbon, Valérie Courgnaud
Abstract: The present disclosure provides compositions and methods for the detection and treatment of cancer. Specifically, the compositions of the present technology include novel DOTA-haptens that may be complexed with a radioisotope (e.g., 225Ac). Also disclosed herein are methods of the using the DOTA-haptens of the present technology in diagnostic imaging as well as pretargeted radioimmunotherapy.
Type:
Grant
Filed:
July 5, 2018
Date of Patent:
January 31, 2023
Assignee:
Memorial Sloan Kettering Cancer Center
Inventors:
Sarah M. Cheal, Michael McDevitt, Ouathek Ouerfelli, Steven M. Larson, Guangbin Yang
Abstract: Provided herein are imaging agents, antidotes to the imaging agents and methods of using the same to image a thrombus or blood clot or thrombin including sites of thrombin accumulation and to diagnose and treat thrombosis. The imaging agents include an aptamer capable of binding the thrombus or thrombin in particular linked to a reporter moiety. The imaging agents may be used to label the thrombus or sites of thrombin accumulation. Antidotes capable of binding to the aptamer in the imaging agent are also provided. The antidotes may further be linked to a quencher capable of quenching the reporter moiety.
Type:
Grant
Filed:
May 21, 2020
Date of Patent:
January 31, 2023
Assignee:
Duke University
Inventors:
Bruce A. Sullenger, Kady-Ann C. Steen-Burrell, Bethany Powell Gray
Abstract: A cancer targeting composition, kit, and method for treatment of cancer cells overexpressing somatostatin receptors is disclosed. The composition includes a radioisotope, a chelator, and a targeting moiety. The chelator includes a nitrogen ring structure including a tetraazacyclododecane, a triazacyclononane, and/or a tetraazabicyclo [6.6.2] hexadecane derivative. The targeting moiety includes a somatostatin receptor targeting peptide. The somatostatin receptor targeting peptide includes an octreotide derivative. The targeting moiety is chelated to the radioisotope by the chelator whereby the cancer cells are targeted for elimination.
Type:
Grant
Filed:
January 12, 2018
Date of Patent:
January 3, 2023
Assignees:
RADIOMEDIXINC., ORANO MED
Inventors:
Izabela Tworowska, Nilesh Wagh, Ebrahim S. Delpassand, Federico Rojas-Quijano, Paul Jurek, Garry E. Kiefer, Tania A. Stallons, Amal Saidi, Julien Torgue
Abstract: Disclosed herein is a method for coupling a first compound having the formula (I) with a second compound that contains a carbonyl group. Also disclosed herein are compounds that can be formed by this method, and uses for such compounds.
Type:
Grant
Filed:
June 12, 2020
Date of Patent:
January 3, 2023
Assignees:
Australian Nuclear Science and Technology Organisation, The Australian National University
Inventors:
Suzanne Virginia Smith, Eskender Mume, Gary James Perkins
Abstract: Disclosed herein is a method for coupling a first compound having the formula (I) with a second compound that contains a carbonyl group. Also disclosed herein are compounds that can be formed by this method, and uses for such compounds.
Type:
Grant
Filed:
June 12, 2020
Date of Patent:
December 27, 2022
Assignees:
Australian Nuclear Science and Technology Organisation, The Australian National University
Inventors:
Suzanne Virginia Smith, Eskender Mume, Gary James Perkins
Abstract: Embodiments of the invention provide methods of synthesizing 18F-tetrafluoroborate (18F-TFB) via direct radiofluorination on boron trifluoride (BF3) to enhance both labeling yield and specific activity. Uses of 18F-TFB are also contemplated.
Type:
Grant
Filed:
April 24, 2017
Date of Patent:
December 20, 2022
Assignee:
Mayo Foundation for Medical Education and Research
Abstract: Radiolabeled anti-LAG3 antibodies and their use in immuno-PET imaging are provided herein. Included are methods of detecting the presence of LAG3 proteins in a patient or sample.
Type:
Grant
Filed:
December 18, 2020
Date of Patent:
November 29, 2022
Assignee:
Regeneron Pharmaceuticals, Inc.
Inventors:
Marcus Kelly, Dangshe Ma, William Olson, Gavin Thurston, Richard Tavare
Abstract: The present disclosure relates to a method for labeling a biomolecule, a fluorescent dye, or a nanoparticle compound with a radioisotope, comprising: (a) providing a cyclooctyne compound represented by the following formula (I) comprising the biomolecule, the fluorescent dye, or the nanoparticle compound which is bound to a cyclooctyne moiety of the cyclooctyne compound; and (b) reacting the cyclooctyne compound of formula (I) with a quinone compound represented by the following formula (II) to give a biomolecule, a fluorescent dye, or a nanoparticle compound labeled with the radioisotope: in formula (I), (Z is the biomolecule, the fluorescent dye, or the nanoparticle compound) in formula (II), (b is 0 or an integer from 1 to 10; L is CH2, —COO—, or —CONH—; M is the radioisotope).
Type:
Grant
Filed:
June 10, 2020
Date of Patent:
November 15, 2022
Assignee:
Korea Atomic Energy Research Institute
Inventors:
Sang Hyun Park, Sajid Mushtaq, Dae Seong Choi
Abstract: The present invention provides bi-terminal PEGylated peptide conjugates that target an integrin such as ?v?6 integrin. In particular embodiments, the peptide conjugates of the present invention further comprise a biological agent such as an imaging agent or a therapeutic agent, e.g., covalently attached to one of the PEG moieties. The peptide conjugates of the present invention are particularly useful for imaging a tumor, organ, or tissue and for treating integrin-mediated diseases and disorders such as cancer, inflammatory diseases, autoimmune diseases, chronic fibrosis, chronic obstructive pulmonary disease (COPD), lung emphysema, and chronic wounding skin disease. Compositions and kits containing the peptide conjugates of the present invention find utility in a wide range of applications including, e.g., in vivo imaging and immunotherapy.
Type:
Grant
Filed:
December 22, 2020
Date of Patent:
November 1, 2022
Assignee:
The Regents of the University of California
Abstract: Provided herein are conjugates including a polypeptide and one or more drug molecules. The polypeptide includes one or more charged motifs, and may further include one or more uncharged motifs. The conjugates may be used to effectively deliver the drug molecule to a subject.
Abstract: Cellular targets on cancer cells have been identified that can be used with targeted molecular imaging to detect the cancer cells in vivo. Non-invasive methods for detecting cancer cells, such as metastasized cancer cells, are therefore provided. Also provided are compositions and kits for use in the disclosed methods.
Type:
Grant
Filed:
September 9, 2019
Date of Patent:
October 4, 2022
Assignees:
H. Lee Moffitt Cancer Center and Research Institute, Inc., Arizona Board of Regents on Behalf of the University of /Arizona
Inventors:
David L. Morse, Robert J. Gillies, Amanda Huynh, Josef Vagner
Abstract: The present invention provides methods of monitoring and measuring tumor-associated free PSA (“fPSA”) with antibody polypeptides as an indication of androgen receptor signaling. In a particular embodiment, the methods may be used to assess the efficacy of anti-androgen and/or general anti-cancer treatments. The present invention also provides various methods and compositions relating to antibodies that are specific for tumor-associated or intratumoral fPSA. For example, the present invention provides compositions, including pharmaceutical compositions, comprising anti-fPSA antibodies, or fragments or characteristic portions thereof. The present invention further provides various therapeutic and/or diagnostic methods of using anti-fPSA antibodies and/or compositions.
Type:
Grant
Filed:
June 3, 2019
Date of Patent:
September 20, 2022
Assignee:
Memorial Sloan Kettering Cancer Center
Inventors:
Charles Sawyers, David Ulmert, Jason Lewis, Michael Evans, Hans Lija
Abstract: The present invention relates to conjugates including a chelating moiety of a metal complex thereof and a therapeutic or targeting moiety, methods for their production, and uses thereof.
Type:
Grant
Filed:
May 4, 2018
Date of Patent:
September 6, 2022
Assignee:
Centre for Probe Development and Commercialization
Inventors:
Eric Steven Burak, John Richard Forbes, Matthew David Burr Moran, Ryan Wayne Simms, John Fitzmaurice Valliant, Alla Darwish
Abstract: Provided herein are protein contrast agents and targeted protein contrast agents, formulations thereof, and methods of use, including but not limited to, as a magnetic resonance imaging contrast agent.
Type:
Grant
Filed:
September 9, 2020
Date of Patent:
August 30, 2022
Assignee:
Georgia State University Research Foundation, Inc.
Inventors:
Jenny Jie Yang, Fan Pu, Shenghui Xue, Jingjuan Qiao, Shanshan Tan, Mani Salarian
Abstract: Provided herein are protein contrast agents and targeted protein contrast agents, formulations thereof, and methods of use, including but not limited to, as a magnetic resonance imaging contrast agent.
Type:
Grant
Filed:
September 9, 2020
Date of Patent:
August 23, 2022
Assignee:
Georgia State University Research Foundation, Inc.
Inventors:
Jenny Jie Yang, Fan Pu, Shenghui Xue, Jingjuan Qiao, Shanshan Tan, Mani Salarian
Abstract: Disclosed are monoacylated Toll-like receptor 2 ligands which can be used in both the development of targeted agents for the imaging and treatment of pancreatic cancer as well as other cancers, and as an adjuvant for cancer immunotherapy. The monoacylated compounds disclosed herein have a higher binding affinity for TLR2 relative to a known potent diacylated agonists, but only ?½ the bioactivity. Competition of the monoacylated compound with the diacylated compound for binding TLR2 was confirmed. Hence, the reported monoacylated compounds are inhibitors/antagonists of TLR2 activation.
Type:
Grant
Filed:
October 5, 2020
Date of Patent:
August 16, 2022
Assignees:
H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC., THE ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA, UNIVERSITY OF SOUTH FLORIDA
Inventors:
David L. Morse, Josef Vagner, Mark McLaughlin, Robert Gillies, Amanda Huynh, Michael Doligalski
Abstract: The present invention provides compounds that have motifs that target the compounds to cells that express integrins. In particular, the compounds have peptides with one or more RD motifs conjugated to an agent selected from an imaging agent and a targeting agent. The compounds may be used to detect, monitor and treat a variety of disorders mediated by integrins.
Type:
Grant
Filed:
September 10, 2020
Date of Patent:
August 16, 2022
Assignee:
WASHINGTON UNIVERSITY
Inventors:
Samuel Achilefu, Kexian Liang, Rui Tang
Abstract: The present disclosure relates to Fibroblast Growth Factor Receptor 2-specific peptide reagents, methods for detecting epithelial-derived cancer cells such as esophageal, colorectal, gastric, pancreatic or breast carcinoma cells using the peptide reagents, and methods for targeting such cells using the peptide reagents.
Type:
Grant
Filed:
June 20, 2018
Date of Patent:
August 9, 2022
Assignee:
THE REGENTS OF THE UNIVERSITY OF MICHIGAN
Abstract: The present invention relates to nanoparticles. In particular, the present invention provides nanoparticles for clinical (e.g., targeted therapeutic), diagnostic (e.g., imaging), and research applications in the field of cardiology. For example, in some embodiments, the present invention provides a method of treating (e.g., ablating) cardiac tissue, comprising: a) contacting an animal with a nanoparticle comprising a matrix, a toxic (e.g., ablative) agent (e.g., sonosensitizer, chemotherapeutic agent (e.g., doxorubicin or cisplatin), or photosensitizer), and a cardiac targeting moiety; and b) administering an activator of the toxic agent (e.g., light, chemical (e.g., pharmaceutical agent) or ultrasound) to at least a portion of the cardiac tissue (e.g., heart) of the animal to activate the toxic agent.
Type:
Grant
Filed:
December 10, 2019
Date of Patent:
June 28, 2022
Assignee:
THE REGENTS OF THE UNIVERSITY OF MICHIGAN
Inventors:
Jerome Kalifa, Raoul Kopelman, Uma Mahesh R. Avula, Gwangseong Kim, Yong-Eun Koo Lee, Hyung Ki Yoon